ClinicalTrials.gg
Active, not recruitingNCT05055323Updated Jul 21, 2026

A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer

A Phase 1 interventional study of Pyrvinium Pamoate in Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8 and Stage I Pancreatic Cancer AJCC v8, sponsored by Thomas Jefferson University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Thomas Jefferson University · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
1,066th of 1,573
20 · median 37
Started
2021
with 87 others
Phase 1
555 of 1,850
74 open now
Primary completion
2024-08
later than 28 of 468 live
Registered
1,443rd of 1,850
by date

Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 1,066th largest by enrollment of the 1,573 interventional ones that give a count, is one of 88 that started in 2021, is one of 555 in phase 1, reaches primary completion later than 28 of the 468 other live ones, and was the 1,443rd registered.

Pancreatic Neoplasms

3,904 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

292 more — sign in →

All 297 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,850 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This phase I trial studies the side effects and best dose of pyrvinium pamoate for the treatment of pancreatic ductal adenocarcinoma that cannot be removed by surgery (resectable). Pyrvinium pamoate may slow down tumor growth and help patients live longer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine the safety and tolerability of pyrvinium pamoate (PP), dosed orally, in patients with pancreatic ductal adenocarcinoma (PDAC) that are surgical candidates.

SECONDARY OBJECTIVE:

I. Assessment of PP's pharmacokinetic and pharmacodynamic (PK/PD) profile and bioavailability in humans.

OUTLINE: This is a dose-escalation study.

Patients receive pyrvinium pamoate orally (PO) once daily (QD) for 3 days in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.

After completion of study treatment, patients are followed up for 30 days and then every week for up to 4 weeks.

03

Conditions studied

  • Resectable Pancreatic Ductal Adenocarcinoma
  • Stage 0 Pancreatic Cancer AJCC v8
  • Stage I Pancreatic Cancer AJCC v8
  • Stage IA Pancreatic Cancer AJCC v8
  • Stage IB Pancreatic Cancer AJCC v8
  • Stage II Pancreatic Cancer AJCC v8
  • Stage IIA Pancreatic Cancer AJCC v8
  • Stage IIB Pancreatic Cancer AJCC v8
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of pancreatic ductal adenocarcinoma (PDAC) suspected preoperatively who are deemed to be surgical candidates by the Thomas Jefferson University surgery department. Patients will be assessed by the pancreatic surgeons in the pancreatic surgery clinic, and if they are found to have resectable disease, they can be considered for this study
  • Patients must not be on therapy, or have received their last neoadjuvant treatment greater than or equal to within three weeks of starting PP therapy
  • Provide signed and dated form
  • Willing to comply with all study procedures and be available for the duration of the study
  • Patients must have an estimated of > 3 months, and (ECOG) performance status of 0-1
  • All patients regardless of age or gender must agree to observe proper methods as to avoid becoming pregnant or causing pregnancy for the duration of the study (30 days after last dose of drug)

    • Males will practice safe sex methods (i.e. condoms)
    • Women of child bearing potential will practice safe sex methods (i.e. condoms, birth control), if a female on the study is of child-bearing age, they will have to take a urine human chorionic gonadotropin (HCG) (pregnancy) test prior to enrolling on the study

Exclusion criteria

Exclusion Criteria:

  • Patients with ongoing anticancer therapies, or those who will have received an anticancer therapeutic \<3 weeks prior to the first dose of PP
  • Any condition that precludes pancreatic surgical resection at the time of the study
  • Pregnancy or currently breastfeeding
  • Known allergic reactions to components of the study product(s): pyrvinium pamoate/ pyrvinium embonate (Molevac)
  • Patients with chronic bowel conditions (such as inflammatory bowel disease (IBD))
  • Kidney function impairment (serum creatine > 1.5 x or creatine clearance \</= 60 ml/1.73m\^2 fr patients with creatine levels > 1.5 x ULN).
  • Patients with liver function impairment: Alkaline phosphatase, and AST above three folds the normal limit (see normal ranges); Total level > 3mg/dl; Albumin \< 3g/dl

    * Alkaline phosphatase:

    • 0-9 years (yr): 83-280 IU/L at 37 degrees Celsius
    • 10-14 yr: 91-400
    • 15-17 yr: 37-240
    • 18-49 yr: 29-92
    • 50-74 yr: 25-120
    • 75-97 yr: 29-160
    • 98-99 yr: 29-120
    • > 99 yr: 29-160
  • Patients with liver function impairment outside of the below ranges

    * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]):

    ** Male (M): 1-45 IU/L at 37 degrees Celsius

    ** Female (F): 1-30

  • Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]):

    • M: 7-42 IU/L at 37 degrees Celsius
    • F: 7-35
  • Patients with liver function impairment outside of the below ranges

    * Albumin:

    • 0-1 yr: 2.6-4.4
    • 1-15 yr: 3.0-4.7
    • 16-99 yr: 3.2-4.9
  • Patients with liver function impairment outside of the below ranges

    * Bilirubin, total:

    ** 0.1-0.9 mg/dL

  • Patients with liver function impairment outside of the below ranges * Protein, total:

    • 0-1 yr: 4.6-7.2 g/dL
    • 1-15 yr: 5.7-8.2
    • 16-99 yr: 6.0-8.5
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment (pyrvinium pamoate)

    Patients receive pyrvinium pamoate PO QD for 3 days in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.

    Drug: Pyrvinium Pamoate

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of dose limited toxicity (DLT)

    Considered any grade 3 or higher adverse event due to the drug itself or delay of surgery. Research coordinator will call patient every day to monitor for DLTs.

    Time frame: Up to 30 days from last dose

Secondary outcomes

  1. Profile of pyrvinium pamoate (PP)

    Will be assessed using liquid chromatography followed by mass spectrometry (LC/MS).

    Time frame: At Start of Treatment

  2. Profile of pyrvinium pamoate (PP)

    Will be assessed using liquid chromatography followed by mass spectrometry (LC/MS).

    Time frame: Completion of treatment

  3. Bioavailability of PP

    Will be assessed using liquid chromatography followed by mass spectrometry (LC/MS).

    Time frame: Up to 4 weeks

  4. Fatty tissue accumulation of PP

    Will be assessed using liquid chromatography followed by mass spectrometry (LC/MS).

    Time frame: Up to 4 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Ponzini FM, Schultz CW, Leiby BE, Cannaday S, Yeo T, Posey J, Bowne WB, Yeo C, Brody JR, Lavu H, Nevler A. Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma. BMJ Open. 2023 Oct 17;13(10):e073839. doi: 10.1136/bmjopen-2023-073839. PubMed 37848297 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Aug 2024, 36 months.

Of 209 non-industry phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 74. This study's 36 months is below that.

Counting every sponsor, half of 380 studies reached it within 45 months; a quarter within 32 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2021
First posted
Sep 24, 2021
StartActual
Jul 29, 2021
Primary completionActual
Aug 1, 2024
CompletionEst.
Dec 31, 2026
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05055323
Responsible party
Sponsor
First posted
Sep 24, 2021
Start date
Jul 29, 2021
Primary completion
Aug 1, 2024
Completion
Dec 31, 2026 (estimated)
Last update
Jul 21, 2026

Study contacts

Harish Lavu, MD
principal investigator · Thomas Jefferson University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pyrvinium

Start the discussion